Pharma BD Deal Intelligence
Industry coverage characterized the deal as a logical bolt-on giving Thermo a defensible IC franchise and the Chromeleon software stack as a data-management…
Thermo Fisher to pay $118.50/share (~$2.1B) for Dionex, targeting $60M year-three synergies and $0.13-0.15 first-year EPS accretion; Dionex's IC and Chromeleon…
Thermo Fisher closed the Dionex acquisition after extended antitrust review, completing a deal seen as immediately accretive and strategically important for…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Thermo Fisher to acquire Dionex for $118.50/share cash, ~$2.1B. Strengthens chromatography portfolio complementing mass spec/LIMS leadership.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Thermo Fisher Scientific Inc. / Dionex Corporation (this deal) | 2010 | $2.1B | 76 |
| Thermo Fisher Scientific Inc. / Patheon N.V. | 2017 | $7.2B | 89 |
| Thermo Fisher Scientific Inc. / Life Technologies Corporation | 2013 | $15.1B | 84 |
| Thermo Fisher Scientific Inc. / PPD Inc. | 2021 | $17.4B | 77 |
| Thermo Fisher Scientific Inc. / Henogen S.A. (Novasep viral vector business) | 2021 | $875M | — |
| Thermo Fisher Scientific Inc. / Brammer Bio | 2019 | $1.7B | — |
| Thermo Fisher Scientific Inc. / Clario Holdings, Inc. | 2025 | $9.4B | — |
← Browse all deals · How we score deals
More: 2010 deals · Thermo Fisher Scientific Inc. deals · Other deals